IPO

With booming Q1 results and hundreds of new hotels, China's H World Group leverages its lean franchise model for aggressive expansion across Asia Pacific.

A new oral drug for depression shows rapid, robust effects in a key trial, offering hope for millions by targeting a different brain pathway.

Amid cannabis market woes, SpringBig slashes costs to reach positive Adjusted EBITDA. Can its AI platform and a bold push into gaming save the company?

DFIN appoints its first-ever Chief Revenue Officer, Ken Napolitano, signaling a strategic overhaul aimed at accelerating growth in a competitive market.

After a decade-long legal battle, minority shareholders of e-commerce firm Dangdang secured a $21M settlement over an allegedly unfair merger.

VR Resources and Athos Metals have launched a massive airborne survey in Ontario, seeking copper, nickel, and PGMs essential for the green economy.

A new $17.9M government contract will fund an AI to analyze phone data, aiming to revolutionize how we detect and treat behavioral health issues.

The new platform introduces an AI 'agent' to unify data, automate execution, and transform sales coaching, moving beyond reactive reports to real-time action.

With a new CFO known for big-ticket financing and IPO readiness, clinical-stage OnCusp Therapeutics is gearing up for its next major growth spurt.

Fresh off its IPO, Agomab Therapeutics is presenting key data for its new IPF drug, AGMB-447, while courting investors on a multi-conference tour.

Former Meta exec Bar Clara Mendez McConnon is launching a new firm to bridge global capital with Israeli innovation, reversing a long-standing investment flow.

Japanese auto software firm Micware hits Nasdaq, raising $22.8M to power next-gen vehicle tech and challenge the industry's global giants.

METiS TechBio's stock surged over 170% on its debut, as investors bet big on its AI-powered platform to build the future of precision drug delivery.

New Pacific Metals reports a Q3 net loss but holds a strong $39M in capital, securing a crucial community agreement for its Carangas project in Bolivia.

Insurtech leader Ethos releases a significant block of shares, providing liquidity to early backers and setting up a major test for the stock and the sector.

With 799% revenue growth and major Fortune 10 deals, Energous proves wireless power is no longer a gadget gimmick but essential industrial tech.

The insurtech's capital-light model shines with soaring revenue and adjusted profits, proving the power of its Risk Exchange despite a reported net loss.

With strong HIFU revenue and new clinical trials, EDAP TMS's upcoming Investor Day will reveal its strategy for medtech dominance and investor confidence.

As the space economy booms, a top TMT research firm launches dedicated coverage, signaling a new era of financial scrutiny for giants like SpaceX and Rocket Lab.

A new six-month semaglutide implant is entering clinical trials, aiming to solve the adherence crisis plaguing GLP-1 drugs like Ozempic and Wegovy.